Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Fulcrum Therapeutics, Inc. (NASDAQ: FULC - Get Free Report) have earned an average recommendation of "Moderate Buy" from the ten research firms that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating